- Wealth Awesome
- Posts
- 📈 🇨🇦 TSX Movers: Top Gainers & Losers (Feb 7th)
📈 🇨🇦 TSX Movers: Top Gainers & Losers (Feb 7th)
Week Ending Feb 7th 2025
Qayyum Rajan
February 08, 2025
Here's a summary of the top-performing and underperforming stocks on the Toronto Stock Exchange (TSX) over the past week (Feb 3-7):
🚀 Top Gainers
Symbol | Company Name | Last Price (CAD) | % Change |
|---|---|---|---|
Converge Technology Solutions Corp | $5.41 | 🟩 +53.26% | |
Tenaz Energy Corp | $15.25 | 🟩 +10.91% | |
AcuityAds Holdings Inc | $2.87 | 🟩 +6.30% | |
EcoSynthetix Inc | $4.73 | 🟩 +6.29% | |
Mineros S.A. | $2.10 | 🟩 +5.53% |
SPONSORED
Join us in simplifying moving.
Moving doesn’t have to be overwhelming. From narrowing down where to live to making it all happen, we simplify the journey every step of the way.
Read the Offering information carefully before investing. It contains details of the issuer’s business, risks, charges, expenses, and other information, which should be considered before investing. Obtain a Form C and Offering Memorandum at https://wefunder.com/lookyloo
📉 Top Losers
Symbol | Company Name | Last Price (CAD) | % Change |
|---|---|---|---|
McEwen Mining Inc | $10.54 | 🟥 -15.00% | |
Briacell Therapeutics Corp | $5.35 | 🟥 -7.28% | |
Tucows Inc | $21.07 | 🟥 -6.69% | |
BCE Inc | $31.62 | 🟥 -6.17% | |
Open Text Corp | $39.77 | 🟥 -5.89% |
📌 Market Highlights
Converge Technology Solutions Corp (CTS-T)
Strategic Acquisition: Converge announced the acquisition of a leading cloud services provider, significantly enhancing its service offerings and market reach.
Tenaz Energy (TNZ-T)
Analyst Upgrades: National Bank Financial initiated coverage on Tenaz Energy with an Outperform rating and a C$23.00 price target, citing its strong leadership under CEO Anthony Marino and a strategic acquisition approach focused on undercapitalized assets. The firm highlighted Tenaz's global expansion strategy, particularly in Europe, South America, the Middle East, and North Africa
McEwen Mining Inc (MUX-T)
Private Placement: Recently announced a private placement of $95 million in convertible senior notes, leading to a 13.2% decline in its stock price due to investor concerns over potential dilution
Briacell Therapeutics Corp (BCT-T)
Clinical Trial Update: On February 3, 2025, BriaCell shared results from its metastatic breast cancer trial, highlighting a clinical response in a patient treated with its Bria-OTS immunotherapy. Despite this positive outcome, the stock experienced a 4.71% decline, possibly due to broader market reactions or investor expectations
Reply